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Abstract
Elastase-mediated cleavage of cyclin E generates low molecular weight cyclin E (LMW-E) isoforms exhibiting enhanced
CDK2–associated kinase activity and resistance to inhibition by CDK inhibitors p21 and p27. Approximately 27% of breast
cancers express high LMW-E protein levels, which significantly correlates with poor survival. The objective of this study was
to identify the signaling pathway(s) deregulated by LMW-E expression in breast cancer patients and to identify
pharmaceutical agents to effectively target this pathway. Ectopic LMW-E expression in nontumorigenic human mammary
epithelial cells (hMECs) was sufficient to generate xenografts with greater tumorigenic potential than full-length cyclin E,
and the tumorigenicity was augmented by in vivo passaging. However, cyclin E mutants unable to interact with CDK2
protected hMECs from tumor development. When hMECs were cultured on Matrigel, LMW-E mediated aberrant acinar
morphogenesis, including enlargement of acinar structures and formation of multi-acinar complexes, as denoted by
reduced BIM and elevated Ki67 expression. Similarly, inducible expression of LMW-E in transgenic mice generated hyper-
proliferative terminal end buds resulting in enhanced mammary tumor development. Reverse-phase protein array assay of
276 breast tumor patient samples and cells cultured on monolayer and in three-dimensional Matrigel demonstrated that, in
terms of protein expression profile, hMECs cultured in Matrigel more closely resembled patient tissues than did cells
cultured on monolayer. Additionally, the b-Raf-ERK1/2-mTOR pathway was activated in LMW-E–expressing patient samples,
and activation of this pathway was associated with poor disease-specific survival. Combination treatment using roscovitine
(CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (a pan kinase inhibitor targeting b-Raf) effectively
prevented aberrant acinar formation in LMW-E–expressing cells by inducing G1/S cell cycle arrest. LMW-E requires CDK2–
associated kinase activity to induce mammary tumor formation by disrupting acinar development. The b-Raf-ERK1/2-mTOR
signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with
roscovitine plus either rapamycin or sorafenib.
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Introduction
Cyclin E has been extensively implicated in breast cancer [1–7].
The function of cyclin E is modulated via association of cyclin E
with CDK2, which promotes progression of cells into S phase [8–
10]. In addition to demonstrating genomic and transcriptional
amplification of the cyclin E gene in breast cancer cells [11], our
laboratory initially reported that cyclin E is cleaved by elastase into
low molecular weight (LMW) isoforms in breast cancers [12,13].
Cleavage of cyclin E occurs at two N-terminal sites of full-length
cyclin E (EL), giving rise to trunk 1 [LMW-E(T1)] and trunk 2
[LMW-E(T2)] isoforms. Compared to EL, the LMW-E isoforms
have higher CDK2-associated kinase activity, are more resistant to
inhibition by CDK inhibitors p21 and p27, and induce higher
proliferation rates when introduced into cells [14,15]. Further-
more, examination of breast cancer patient samples revealed that
approximately 27% of patients express high LMW-E protein levels
as assessed by Western blot analysis, and high LMW-E expression
significantly correlates with poor survival [16].
Although the connection between LMW-E and breast cancer
outcome is clear, understanding of how LMW-E influences
mammary tumor formation is lacking. In the mammary gland,
the acinus is composed of a bilayer of luminal epithelial cells and
basal myoepithelial cells; the lumen of each acinus is hollow and
contains milk secretions during lactation [17,18]. Human
mammary epithelial cells (hMECs) cultured on a reconstituted
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tiation to form highly organized and polarized acinar structures
[19,20]. Although this system serves as an excellent model for
studying breast cancer development in vitro, a direct comparison of
the proteomic profiles of hMECs in culture and the proteomic
profiles of patient tissues has not been reported.
Most studies aimed at elucidating the action of specific proteins
in breast tumorigenesis or identifying inhibitors of proteins that
warrant testing in clinical trials have been conducted using the
traditional two-dimensional (2D) culture. However, 2D culture do
not reflect the important contribution of the tissue microenviron-
ment both in mediation of normal breast tissue viability and in
generation of the apoptotic-resistant phenotype of breast tumors.
Culturing of cells in three-dimensional (3D) matrices offers several
advantages over 2D culture. Culturing cells in 3D matrices allows
cells to organize into structures that mimic their in vivo
architecture, and 3D culture is particularly useful for investigating
gene functions and signaling pathways in a physiologically relevant
context. In 3D culture, normal and nonmalignant hMECs can be
distinguished from premalignant cells: whereas normal cells
become quiescent by day 10 and organize into replicas of human
breast acini with correct tissue polarity and proportions [19,20],
malignant cells continue to grow, pile up, and form large,
disorganized, tumor-like colonies [21]. Additionally, 3D culture is
superior to 2D culture for identifying the driving oncogenic
pathways in tumor cells and the critical inhibitors that warrant
testing in therapeutic trials [22–24]. Here, we used 3D culture to
elucidate the mechanisms by which LMW-E leads to progression
of breast cancer, as manifested by deregulated mammary acinar
morphogenesis, increased tumorigenic potential, and altered
activation of targetable signal transduction pathways identified
from patient samples.
Specifically, we provide evidence suggesting that the LMW-E/
CDK2 complex induces breast tumor initiation and progression by
disrupting the architecture of the mammary gland. Through
proteomic analysis of both LMW-E-overexpressing hMECs and
tumor tissue from breast cancer patients, we identify the b-Raf-
ERK1/2-mTOR pathway to be critical in the tumorigenic
properties of LMW-E. Consequently, we show that the disruption
of the mammary gland architecture mediated by LMW-E/CDK2
can be effectively prevented by combination treatment with
roscovitine (inhibitor of CDKs) plus either rapamycin (inhibitor of
mTOR) or sorafenib (a pan kinase inhibitor that has activity
against b-Raf). Early steps in breast tumorigenesis are character-
ized by enhanced proliferation of epithelial cells and deregulated
acinar formation, including enlargement of acinar structures and
filling of the luminal space [21]. In this study, we report that the
phenotypes mediated by LMW-E during acinar development
closely resemble those of human mammary epithelial cells in the
early steps of breast cancer development. Additionally, inducible
LMW-E expression in transgenic mice generates hyper-prolifera-
tive terminal end buds (TEBs) resulting in enhanced mammary
tumor development and metastasis. Finally, through proteomic
analysis, we provide evidence that breast cancer patient samples
and cells cultured in 3D matrices display a high degree of
concordance, thus further supporting the usefulness of this in vitro
culture system.
Results
LMW-E renders hMECs tumorigenic, and LMW-E
expression is selected with increased in vivo passaging
The presence of LMW-E in breast cancer patient samples as well
as cell lines but not in normal tissues suggests that the LMW-E
isoforms contribute to the development of breast cancer [13,16,25].
Therefore,we examined whetherectopicexpressionofLMW-Eina
nontumorigenic cell line could render it tumorigenic. 76NE6 cells
(hMECs) stably expressing vector, EL, or LMW-E (‘‘76NE6-
vector’’, ‘‘76NE6-EL’’, and ‘‘76NE6-LMW-E’’, respectively) were
injected subcutaneouslyinto nude mice, and xenograftdevelopment
was monitored. Only 7% (1/15) of the mice injected with 76NE6-
EL cells developed tumors as compared with 74% (23/31) of the
mice injected with the 76NE6-LMW-E cells (p,0.0001) (Table 1).
To investigate if LMW-E expression in hMECs is sufficient to
maintain tumor growth and to determine whether cells from
tumors generated by LMW-E-expressing hMECs can form new
tumors, LMW-E-expressing tumor cells (TDCs: tumor-derived
cells) were subjected to serial in vivo passaging in mice. More
Table 1. LMW-E is tumorigenic.
Tumors/Injections (%)
76NE6-vector 0/12 (0%)
76NE6-EL 1/15 (7%)
76NE6-LMW-E 23/31 (74%)
T1G2.2 5/5 (100%)
T1G2.7 5/5 (100%)
T1G3.7 5/5 (100%)
T1G3.8 5/5 (100%)
MDA-MB-468 11/11 (100%)
Athymic mice were injected subcutaneously with 1610
7 76NE6 cells stably
transfected with empty vector, EL, LMW-E and MDA-MB-468 cells. After 10
weeks, the tumors were removed for expansion in culture for further in vivo
passaging and also for IHC analysis. Tumor incidence rate was estimated with
exact 95% confidence intervals and Fisher’s exact tests were used to compare
tumor incidence rate between/among groups (*p,0.0001: 76NE6-vector vs.
76NE6-LMW-E; 76NE6-EL vs. 76NE6-LMW-E; 76NE6-vector vs. TDCs; 76NE6-EL vs.
TDCs).
doi:10.1371/journal.pgen.1002538.t001
Author Summary
Effective cancer treatment should include targeting not
only drivers of tumorigenicity but also the downstream
signaling pathways that these drivers activate. Special
attention has to be given to the model systems that
identify these targets and interrogating if these targets are
poor prognostic indicators in patients. Using cell lines
cultured on plastic and extracellular matrix (Matrigel) and
comparing their proteomic profiles to breast cancer tumor
samples, we demonstrated that overexpression of LMW-E
is concomitant with activation of the b-Raf-ERK1/2-mTOR
pathway. Using mouse models, we show that induction of
LMW-E is sufficient to induce mammary tumor develop-
ment in vivo. Next, cells established from the tumors were
treated with combination therapy targeting the LMW-E/
CDK2 complex and the b-Raf-ERK1/2-mTOR pathway.
Results revealed that this combination therapy effectively
inhibited the altered proliferation of these cells. Most
significantly, we showed that breast cancer patients whose
tumors overexpress both LMW-E and different compo-
nents of the b-Raf-ERK1/2-mTOR pathway have the worst
prognosis. In summary, through the use of multiple in vitro
and in vivo model systems and translating the findings to
clinical specimens, we have identified a novel targeted
therapy in breast cancer patients whose tumors overex-
press LMW-E.
LMW-E Identifies b-Raf-Erk1/2-mTOR Pathway in BC
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expansion, and two T1G2 clones were injected into mice to
generate the T1G3 clones (Figure 1A). This process was repeated
to generate three total generations of in vivo passaged clones
(T1G2, T1G3, and T1G4). Interestingly, re-injection of the
isolated cells from the tumors resulted in 100% tumor formation,
suggesting that these cells became more tumorigenic during the
process of in vivo passaging (Table 1).
Western blot analysis indicated that the majority of the TDCs
had higher LMW-E expression than the 76NE6-LMW-E cells
(Figure 1B). Furthermore, quantification of the cyclin E protein
levels by densitometry indicated that in vivo passaging resulted in
sequential reduction in the level of EL (Figure 1C) and an increase
in the level of LMW-E protein with each generation of passaging
(Figure 1D). The protein level of elafin (an endogenous inhibitor of
the serine protease responsible for cleaving cyclin E into LMW-E
isoforms [26]) also diminished with increasing passaging in vivo,
suggesting that cyclin E was subjected to elevated proteolytic
processing in the mouse microenvironment (Figure 1E). Addition-
ally, immunohistochemical analysis of the xenograft tumors from
the mice revealed strong cyclin E expression throughout the
tumors and a number of the cells with enlarged nuclei and
multinucleated morphology (Figure 1F). These findings suggested
not only that LMW-E is tumorigenic, but also that continued
expression of LMW-E provides the cells a growth advantage to
promote their sustained survival in mice.
CDK2–associated kinase activity is required for LMW-E–
mediated tumorigenesis and aberrant acinar
morphogenesis
To examine the role of CDK2 in LMW-E-mediated tumori-
genesis, we generated another model system, as previously
Figure 1. LMW-E renders hMECs tumorigenic, and LMW-E expression is selected with increased in vivo passaging. (A) Schematic of the
generation of in vivo passaged clones with 3 successive injections (T1G2, T1G3, and T1G4). (B) Tumors from in vivo passaging were removed from
mice, minced, and cultured on monolayer plates. Lysates were extracted and subjected to Western blot analysis with antibodies against cyclin E,
elafin, and b-actin. EL (C), LMW-E (D), and elafin (E) protein levels were quantified by densitometry and compared between different generations of in
vivo passaged cells (Student t test, *p,0.05). (F) Paraffin-embedded slides of 4 representative tumors were stained with hematoxylin and eosin (top
panel) and cyclin E antibody (bottom panel).
doi:10.1371/journal.pgen.1002538.g001
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EL, and LMW-E in 76NE6 cells could be induced by varying
doxycycline concentrations (Figure 2A). In vitro kinase assay using
histone H1 and GST-Rb as substrates confirmed that inducible
EL, and LMW-E, had functional cyclin E-associated kinase
activity (Figure 2A). We injected the 76NE6 cells with inducible
protein expression subcutaneously into nude mice and induced the
expression of vector, EL, and LMW-E with doxycycline 24 hours
later. The tumor incidence rates were significantly higher in mice
treated with 500 mg/ml doxycycline than in mice not treated with
doxycycline by Fisher exact test (p,0.0001) (Table 2). In addition,
LMW-E induction with 500 mg/ml doxycycline led to tumor
formation in more than 90% of the injections, whereas EL
induction with 500 mg/ml doxycycline led to tumor formation in
only 17% of mice (Table 2). The tumor incidence rate mediated
by LMW-E in this xenograft model is consistent with the
transgenic model of LMW-E overexpression previously reported
[28].
Since cyclin E is the regulatory subunit of the cyclin E/CDK2
complex and is enzymatically inactive when unbound, we
speculated that the oncogenicity of LMW-E requires interaction
with CDK2. Consequently, we generated a point mutation at
R130A in the cyclin E gene that prevents cyclin E from interacting
with CDK2, thereby suppressing the cyclin E/CDK2 kinase
activity [29]. The CDK2-associated kinase activity of these
inducible mutants was compromised as indicated by lack of
histone H1 and GST-Rb phosphorylation (Figure 2A). To
determine whether cyclin E-mediated tumorigenesis is dependent
on the kinase activity associated with CDK2, we injected 76NE6
cells with inducible expression of EL
R130A and LMW-E
R130A into
nude mice. The resulting tumor incidence was 17% or less for cells
expressing EL
R130A and LMW-E
R130A (Table 2) indicating that
Figure 2. CDK2-associated kinase activity is required for LMW-E-mediated tumorigenesis and deregulation of acinar
morphogenesis. (A) 76NE6-TetR cells were cultured with or without doxycycline induction, and the lysates were extracted and subjected to
Western blot analysis with antibodies against cyclin E, CDK2, and b-actin. In vitro kinase assay was performed by immunoprecipitation with FLAG
antibody and histone H1 and GST-Rb were added as substrates. Doxycycline was administered to achieve approximately 16and 26cyclin E protein
levels. (The doxycycline concentrations for the 76NE6-TetR-V and wild-type EL and LMW-E cells were 0, 0.2, and 0.4 ng/ml, and the doxycycline
concentrations for the EL
R130A and LMW-E
R130A cells were 0, 1, and 2 ng/ml.) (B) 76NE6-TetR cells were cultured on Matrigel for 15 days with or
without doxycycline induction. Bright-field images were taken at day 15. Values underneath each figure represent mean diameter (mm) 6 SEM. (C)
The diameters of at least 100 acini from 3 different experiments were measured. Error bars=SEM (Wilcoxon rank-sum test, *p,0.05). (D) Multi-acinar
complexes were counted. Error bars=SEM (Wilcoxon rank-sum test, *p,0.05). Multi-acinar complexes were defined as complexes with more than 2
acini growing on top of each other. Logistic regression models were used to compare the rate of formation of multi-acinar complexes between/
among groups (*p,0.05).
doi:10.1371/journal.pgen.1002538.g002
LMW-E Identifies b-Raf-Erk1/2-mTOR Pathway in BC
PLoS Genetics | www.plosgenetics.org 4 March 2012 | Volume 8 | Issue 3 | e1002538CDK2-associated kinase activity is necessary for LMW-E-
mediated tumorigenicity. These results demonstrated that cells
expressing LMW-E have a higher frequency of tumor formation
than cells expressing EL, and this oncogenicity is critically
dependent on the CDK2-associated kinase activity. This observa-
tion is consistent with our recently published results in which we
reported that LMW-E overexpression does not induce mammary
tumor development in CDK2
2/2 transgenic mice [28].
We next asked if deregulation of acinar development is
responsible for LMW-E-mediated oncogenicity. Examination of
acinar development of hMECs cultured on a reconstituted
basement membrane revealed that while induced EL expression
led to generation of large acini with the typical spherical structure,
induced LMW-E expression led to generation of large acini with
irregular shapes (Figure 2B). Quantification of the size of the acini
revealed that deregulation of acinar morphogenesis by LMW-E
was dose dependent, with higher cyclin E expression generating
larger acini (Figure 2C). In contrast, induction of EL
R130A and
LMW-E
R130A did not increase acinar size (Figure 2B and 2C).
Furthermore, only wild-type LMW-E expression generated
multi-acinar complexes (complexes with multiple acini forming
aggregate structures), a phenotype not observed with EL,
EL
R130A and LMW-E
R130A expression (Figure 2D). Overall,
our data suggested that LMW-E depends on CDK2-associated
kinase activity to induce mammary tumorigenesis and aberrant
acinar morphogenesis.
LMW-E induces formation of large and highly
proliferative acini
The 3D cell culture system can be used to distinguish
nonmalignant from malignant cells on the basis of the phenotypes
observed [19]. 76NE6 cells and MCF-10A cells (immortalized
hMECs) formed polarized acinar structures when cultured on
Matrigel as indicated by a6-integrin staining on the basal surface
and GM-130 staining on the apical surface (Figure 3A). In
contrast, breast cancer cell lines such as Hs 578T and MDA-MB-
231, which express endogenous LMW-E (Figure 3B) did not form
coherent acini and demonstrated disordered polarity as indicated
by unorganized a6-integrin and GM-130 staining (Figure 3A).
Using 76NE6 cells with stable vector, EL, and LMW-E
expression, we found that, similar to what we observed in cells
with inducible protein expression (Figure 2B), overexpression of
EL led to generation of large but still spherical acini, while
overexpression of LMW-E led to generation of large, irregularly
shaped structures and multi-acinar complexes (Figure 3C).
Aberrant acinar development was also observed in the TDCs, in
which the acini were approximately 28% larger than the structures
formed by the 76NE6 cells with vector expression (p,0.05)
(Figure 3D).
During normal acinar morphogenesis, cells are highly prolifer-
ative and then undergo apoptosis of the lumen with subsequent
proliferative arrest and induction of differentiation by day 15 in
culture [30]. As expected, the 76NE6 cells arrested proliferation by
downregulating cyclin E in 3D culture (Figure 3B). However,
cyclin E protein levels in the 76NE6-LMW-E cells and in the
TDCs were upregulated during acinar morphogenesis compared
to the cyclin E protein levels in the 76NE6-V and 76NE6-EL cells
(Figure 3E). Moreover, the cyclin E-associated kinase activity of
the LMW-E-expressing cells was also elevated, suggesting that cells
in these acinar structures were still actively proliferating, passing
through the G1/S-phase checkpoint and thus leading to formation
of enlarged acini. We also observed that the levels of cyclin E
protein as well as mRNA transcript were much higher in the
76NE6-LMW-E cells compared to the 76NE6-EL cells (Figure 3E
and Figure S1A), which is a phenomenon that was also observed in
the transgenic mouse model with overexpression of LMW-E
(Figure S1B). To test if overexpression of LMW-E in the transgenic
mice upregulates the endogenous mouse cyclin E gene, we
analyzed mouse cyclin E mRNA expression levels in the tumor
and the contralateral mammary gland of 3 different LMW-E-
overexpressing transgenic mice (Figure S1B). Quantitative RT-
PCR analysis showed a 3-fold increase in the abundance of
endogenous cyclin E mRNA in the tumors when compared to the
contralateral mammary glands. These results are consistent with a
model in which, during tumor progression, LMW-E expression
activates a positive feedback loop leading to increase expression of
endogenous cyclin E.
BIM, a member of the Bcl-2 pro-apoptotic family, has been
shown to be responsible for cell death during late acinar
morphogenesis to generate a hollow lumen in the acinus [31].
We found that BIM protein levels were downregulated in the
LMW-E-expressing acini, suggesting that these cells bypass
morphogenetic cues that cause growth arrest and apoptosis of
the luminal cells (Figure 3E). To determine whether LMW-E
expression was sufficient to prevent growth arrest of cells in mature
acini, we fixed acini at 15 days and stained them for Ki67. While
Ki67 expression was not detectable in the 76NE6-V acini, LMW-
E-expressing acini displayed high Ki67 staining, particularly in
cells that were in contact with the basement membrane (Figure 3F
and 3G). Furthermore, we determined a strong positive correlation
between the acinar diameter and the percentage of Ki67-positive
acini, indicating that the formation of large acini may be due to
increased proliferation (Figure 3H). Collectively, these findings
provided evidence that expression of LMW-E is sufficient to
induce generation of large and misshapen acini that exhibit
enhanced cell proliferation and decreased apoptosis. These
phenotypes resemble those observed in ductal carcinoma in situ
and also those caused by ErbB2 activation [21] and may explain
the high tumorigenic potential of LMW-E over EL.
LMW-E induces ductal hyperplasia in vivo and invasion in
Boyden chamber assays
Having shown that LMW-E expression renders hMECs
tumorigenic and leads to altered acinar morphogenesis, we set
out to determine whether there was a direct cause-and-effect
Table 2. The tumorigenicity of LMW-E requires CDK2–
associated kinase activity.
Dox (mg/ml) 0 500
Tumors/Injections (%) Tumors/Injections (%)
vector 1/18 (6) 2/18 (11)
EL 2/18 (11) 3/18 (17)
LMW-E 2/18 (11) 19/20 (95)
EL
R130A 0/8 (0) 1/12 (8)
LMW-E
R130A 0/8 (0) 2/12 (17)
Athymic mice were injected with 1610
7 76NE6-TetR cells with inducible
expression for empty vector, EL, LMW-E, EL
R130A, and LMW-E
R130A. Doxycycline
was added to drinking water containing 1% sucrose 24 hours after injection
and replaced twice weekly. The diameter of the tumors were measured and
recorded weekly. Tumor incidence rate was estimated with exact 95%
confidence intervals and Fisher’s exact tests were used to compare tumor
incidence rate between/among groups (*p,0.0001: LMW-E 0 vs. LMW-E 500;
vector 500 vs. LMW-E 500; EL 500 vs. LMW-E 500; LMW-E 500 vs. EL
R130A 500;
LMW-E 500 vs. LMW-E
R130A).
doi:10.1371/journal.pgen.1002538.t002
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mammary ductal structures in a transgenic mouse model. We
developed transgenic mice with doxycycline-inducible LMW-E
expression and examined these mice for altered TEB formation in
the mammary gland and tumorigenesis in response to induction of
LMW-E expression (Figure 4A). Following 4 days of doxycycline
treatment, MTB/TLMW mice demonstrated a 685-fold increase
in luciferase activity above background for line 4372 and about 39-
fold above background for line 4382 and LMW-E protein
expression was detected by Western blot analysis; however, in
MTB/TLMW mice not treated with doxycycline and in
doxycycline-treated MTB or TLMW mice, no increase in
luciferase activity or LMW-E protein expression was observed
(Figure 4B). Morphological examination of carmine-stained whole
mounts revealed striking hyperplastic abnormalities in mammary
ductal trees of both MTB/TLMW lines of mice with induced
expression of LMW-E (Figure 4C, lower panels). The mammary
glands of these mice displayed abnormal development, including
the formation of solid cellular masses along the primary ducts that
resembled abortive side buds and misshapen TEBs. In contrast,
mammary tissues from MTB/TLMW mice without induced
expression of LMW-E were histologically indistinguishable from
tissues from wild type and MTB mice and had normal club-shaped
TEBs (Figure 4C, upper panels). In addition, the mammary
epithelium of both MTB/TLMW lines with induced LMW-E
expression showed 2-folds higher in BrdU incorporation as
compared to the mammary epithelium of MTB/TLMW mice
without induced LMW-E expression (p=0.03) indicating that
LMW-E overexpression, as shown by immunohistochemistry
(Figure 4D; 34.9%62.7% cyclin E-positive cells for line 4372
and 25.1%61.6% cyclin E-positive cells for line 4382), induces
high proliferation in the mammary epithelium. These data
obtained from the transgenic mice suggested that inducible
LMW-E expression in the mouse mammary epithelium results in
hyper-proliferation and aberrant acinar morphogenesis similar to
what was observed with the hMECs expressing LMW-E cultured
on Matrigel in the xenograft model system.
We have shown previously that approximately 25% of
transgenic mice with LMW-E expression developed metastasis as
compared to 8.3% of tumors with EL overexpression [32].
Cellular invasion is one of the critical events leading to successful
metastasis and requires migration of the tumor cells through the
basement membrane to invade the surrounding tissues [33]. The
Boyden chamber invasion assay was performed to investigate
whether LMW-E expression in hMECs enhances cellular
invasiveness. The cells were seeded on a microporous transwell
insert on top of a thin layer of Matrigel with fibronectin on the
other side of the membrane to act as a chemo-attractant. After
24 hours, the cells that have invaded to the bottom side of the
membrane were stained with crystal violet for visualization.
Figure 4E shows that while the vector control cells were unable
to invade through the Matrigel basement membrane, cells with
cyclin E expression were highly invasive. More specifically,
quantification of the invaded cells demonstrate that while all cells
with cyclin E expression invaded through the basement membrane
significantly more than vector control cells, cells with LMW-E
expression invaded significantly more than cells with EL
expression (p,0.05) (Figure 4F). Collectively, we provide evidence
suggesting that overexpression of LMW-E enhances the invasive-
ness of hMECs.
High LMW-E expression is associated with the activated
b-Raf-ERK1/2-mTOR pathway in vitro and in human
tumor tissues
While it is widely accepted that the 3D culture system serves as a
more physiologically relevant model for the investigation of cell
behavior compared to 2D plastic surface [18,20], no direct
comparison between cells cultured on this 3D model and human
samples has been performed. Therefore, we next aim to compare
the protein expression patterns between cells grown on 2D culture,
3D culture and human breast tumor tissues. The reverse-phase
protein array (RPPA) assay was used to compare the expression
levels of 73 different proteins involved in major signaling
transduction pathways and cellular processes between xenografted
tumor-derived cells (TDCs) grown on 2D monolayer and in 3D
Matrigel cultures and 276 human breast cancer samples previously
described [16]. The RPPA method is a proteomic protein
expression analysis that has been shown to be highly reproducible
in analyzing the expression patterns of proteins involved in cell
signaling [34–36]. For these analyses, serially diluted lysates
prepared from cell lines cultured on 2D and 3D as well as from
276 tumor specimen were arrayed on nitrocellulose-coated slides
as described previously [16]. Each slide was then probed with a
validated primary antibody plus a biotin-conjugated secondary
antibody. Table S1 lists the antibody targets used for this study,
which were selected as being relevant to breast cancer through a
literature review. Hierarchical clustering was then performed using
Euclidean distance and Ward’s minimum variance for agglomer-
ation (Figure 5A). The resulting heat map demonstrated that the
cells from 2D and 3D cultures had strikingly different protein
expression patterns and that the protein expression pattern of the
cells from 3D cultures more closely resembled that of patient
tissues than did the protein expression pattern of cells grown on
monolayer (Figure 5A). Most of the proteins that show a distinct
expression pattern between 2D and 3D cultures play key roles in
cell proliferation, specifically, the G1 to S transition (Table S2).
These results were expected since it has been established that the
3D culture system is a more physiologically relevant model than
cell culture on a 2D plastic surface for the investigation of cellular
behavior [18,20]. Furthermore, in an unsupervised analysis of the
patient RPPA data, we observed separate clustering between the
Figure 3. LMW-E induces formation of large and highly proliferative acini. (A) 76NE6, MCF-10A, HS 578T, and MDA-MB-231 cells were
seeded at a density of 70 cells/mm
2 on 1-mm-thick Matrigel. After 15 days in 3D culture, cells were fixed and immunostained with GM-130 and a6-
integrin antibodies. Nuclei were counterstained with DAPI. Scale bar=50 mm. (B) Lysates from these cells were isolated at days 0 (d0) and 15 (d15) of
acinar morphogenesis and subjected to Western blot analysis with the indicated antibodies. (C and D) 76NE6 cells stably transfected with vector, EL,
and LMW-E and tumor-derived cells (TDCs) were subjected to analysis similar to that in (A) (V=vector). Scale bar=50 mm. The diameters of the acini
were measured and averaged from 3 independent experiments. Values underneath each figure represents mean (mm) 6 SEM. Error bars=SEM
(Student t test, *p,0.05). (E) Lysates from these cells were isolated at day 15 and subjected to Western blot analysis with the indicated antibodies. In
vitro kinase assay was performed by immunoprecipitation of lysates from 3D culture using polyclonal cyclin E antibody and incubation with
(cP32)ATP and GST-Rb. (F and G) Cells cultured on Matrigel for 15 days were fixed and immunostained with E-cadherin and Ki67 antibodies. Nuclei
were counterstained with DAPI. Scale bar=50 mm. The number of Ki67-positive cells per acinus was counted and averaged from 3 independent
experiments. Error bars=SEM (Student t test, *p,0.05). (H) Linear regression of the correlation between acinar diameter and percentage of Ki67-
positive cells.
doi:10.1371/journal.pgen.1002538.g003
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PLoS Genetics | www.plosgenetics.org 7 March 2012 | Volume 8 | Issue 3 | e1002538Figure 4. LMW-E induces ductal hyperplasia in vivo and invasion in Boyden chamber assays. (A) Doxycycline-dependent expression of
LMW-E in MTB/TLMW mice induces ductal hyperplasias. Bi-transgenic mice carrying both the MMTV-rtTA-pA (MTB) transgene and the TetO-LMW-E
(TLMW) transgene express the rtTA transactivator in the mammary epithelium but do not express LMW-E unless doxycycline is added. (B) Virgin
female mice (6 weeks old) of the indicated genotypes were either left untreated or administered 2 mg/ml doxycycline in drinking water for 4 days.
Mammary gland extracts were prepared and subjected to luciferase activity assay and Western blot analysis of LMW-E expression. (C) Whole-mount
staining of mammary glands from 8-week-old mice either left untreated (upper panels) or administered 2 mg/ml doxycycline in drinking water for 7
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low and high full-length cyclin E (Figure S2A and S2B).
We next identified the proteins whose expression was
significantly associated with LMW-E levels as well as patient
survival in the tumor database (Figure 5B). Our analysis revealed
that the b-Raf-ERK1/2-mTOR pathway is activated in the
breast cancer patient samples as well as in the tumor cells
cultured on Matrigel with high LMW-E expression (Figure 5B
and 5C and Table S3). Furthermore, a direct comparison
between the levels of all the proteins analyzed in Figure 5C by
Western blot and those obtained from the RPPA analysis
showed high concordance (Pearson coefficient=0.723,
p,0.001) and also validated the activation of this signaling axis
in vitro (Figure 5C and 5D). Additionally, breast cancer patient
tumors with high LMW-E expression also expressed high levels
of b-Raf, pMEK1/2 (S217), ERK2, mTOR, and eIF4E and a
low level of pAkt (T308) (Table 3 and Figure S3). Collectively,
these data suggested that in terms of proteomic expression
patterns, breast cancer cells grown in 3D culture more closely
r e s e m b l eh u m a nt u m o r st h a nd ob r e a s tc a n c e rc e l l sg r o w ni n2 D
culture thereby underscoring the usefulness of this in vitro model
system.
Combination drug treatment prevents induction of
aberrant acinar development by LMW-E
Having established the importance of the CDK2-associated
kinase activity in aberrant acinar morphogenesis in 3D culture
and given that the b-Raf-ERK1/2-mTOR signaling axis was
deregulated in tumor cells and patient samples with high LMW-
E expression, we hypothesized that combination treatment with
roscovitine (a CDK inhibitor) plus either rapamycin (an mTOR
inhibitor) or sorafenib (a pan kinase inhibitor that has activity
against b-Raf) can prevent the induced-aberrant acinar mor-
phology. Combination treatments of cells cultured in Matrigel
using these agents resulted in a larger reduction of the levels of
pS6 (S235/236), pERK1/2 (T202/Y204), and pRb (S807/811)
than no treatment or treatment with single agents (Figure 6A).
Moreover, the combination treatments upregulated the expres-
sion of the CDK inhibitors p21 and p27, consistent with a cell
cycle arrest at the G1-S phase. Examination of the acinar
formation as a result of the combination drug treatments
revealed that the TDCs displayed a significant reduction in
acinar size and Ki67 levels compared to the untreated cells and
cells treated with single agents (Figure 6B and 6D, Figure S4,
Figure S5A and S5B, and Tables S4 and S5). In contrast, the
76NE6-V and 76NE6-EL cells displayed no change in these
phenotypes in response to the drug treatments, suggesting that
the absence of LMW-E expression may protect these cells from
the toxic effects of the drugs. Thus, roscovitine in combination
with either rapamycin or sorafenib can prevent the development
of the aberrant acinar phenotypes caused by LMW-E expression,
confirming a role for LMW-E/CDK2 kinase activity in causing
formation of large, multilobular acini and demonstrating a
potential therapeutic approach to treat cancer patients with high
LMW-E expression.
Activated b-Raf-ERK1/2-mTOR signaling pathway and
high LMW-E expression predict poor survival
In a large retrospective clinical study, we previously found that
breast cancer patients whose tumors had high levels of LMW-E
expression, as determined by Western blot analysis, have
significantly worse DSS than patients whose tumors had low
LMW-E expression [16]. In the study reported herein, we used
tissue samples from 276 of these patients for RPPA analysis to
investigate large-scale protein expression pattern. The 276 patients
were divided into 4 groups based on both LMW-E and EL
expression and subjected to Kaplan-Meier analysis (Figure 7A).
The four groups consisted of (i) 22 patients with low LMW-E/high
EL, (ii) 92 patients with low LMW-E/low EL, (iii) 33 patients with
high LMW-E/high EL, and (iv) 129 patients with high LMW-E/
low EL. Similar to our previous observation, we found that
patients with high LMW-E protein levels had significantly worse
DSS than patients with low LMW-E expression (p,0.0001)
(Figure 7A). More specifically, only patients whose tumors
overexpress LMW-E (groups iii and iv) regardless of whether or
not they also overexpress EL, have a poor prognosis (Figure 7A).
Additionally, those patients whose tumors overexpress EL, in the
absence of any LMW-E (group i) have the best prognosis. This
new analysis clearly indicated that LMW-E overexpression, but
not EL, is responsible for poor patient outcome.
Next, we performed bivariate analysis of cyclin E level along
with key nodes in the b-Raf-ERK1/2-mTOR pathway, which
revealed that among breast cancer patients with high LMW-E
expression, those with high FAK levels had significantly worse
DSS than those with low FAK levels (p=0.0042) (Figure 7B and
Figure S6). In contrast, among patients with high LMW-E
expression, low BIM or low total Akt levels were associated with
worse survival. Additionally, the overall DSS of patients with high
LMW-E combined with these proteins in the b-Raf-ERK1/2-
mTOR pathway was dramatically worse than in the patients with
high EL expression (Figure 7B and Figure S6).
To determine whether these individual proteins collaborate to
reduce patient survival, we performed multivariate analysis by
analyzing patients with high LMW-E expression and combining 2
additional proteins. We found that patients with high LMW-E,
high FAK, and low BIM, Akt, or pAkt (T308) experienced
significantly worse DSS than the opposite groups (p,0.05)
(Figure 7C). In addition, patients with high LMW-E, low BIM,
and low Akt or pAkt (T308) experienced significantly worse DSS
(p,0.05). Interestingly, we were not able to find statistical
significance between EL expression in the same multivariate
analysis with these proteins (Figure S7). Essentially, our statistical
analysis suggests that it is likely that LMW-E, FAK, BIM, Akt, and
pAkt (T308) function in the same pathway to adversely affect
patient survival with breast cancer.
Discussion
There is mounting evidence suggesting that the LMW-E
isoforms play a unique role in mammary tumorigenesis. Our
current understanding of cell cycle deregulation by LMW-E
consists of enhanced S-phase entry [13], aberrant centrosomal
days (lower panels). TEB, terminal end buds. (D) Representative BrdU and cyclin E analyses performed on mammary sections from MTB/TLMW 6-week-
old females administered doxycycline for 4 days (left panels, magnification:6200). BrdU incorporation and percentage of cyclin E-positive cells were
quantified (right panels) by counting 1,000 cells per section in 3 mice. (E) Boyden Chamber assays. 76NE6 parental and different EL, LMW-E and TDC
variants were seeded on Matrigel-coated transwell chamber and incubated on top of fibronectin-containing media for 24 hours. The cells on top of
the membrane were removed and the cells remaining on the bottom were stained with crystal violet and images were taken with a light microscope.
(F) After 24 hours incubation, the cells on the bottom of the transwell were collected and counted. Statistical analysis used was unpaired student’s t-
test. MDA-MB-231 cells were used as positive control for the invasion assay.
doi:10.1371/journal.pgen.1002538.g004
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PLoS Genetics | www.plosgenetics.org 10 March 2012 | Volume 8 | Issue 3 | e1002538Figure 5. High LMW-E expression is associated with activated b-Raf-ERK1/2-mTOR pathway in vitro and in patient tissues. (A)
Hierarchal cluster analysis of protein expression in 76NE6, 76NE6-LMW-E and all of the LMW-E-expressing tumor clones grown on 2D (red) and 3D
(green) cultures and 276 breast cancer patient samples (blue). (B) Proteins whose expression was associated with high LMW-E levels. Red indicates
that high LMW-E along with high protein expression was associated with poor prognosis; grey indicates that high LMW-E along with low protein
expression was associated with poor prognosis. (C) The lysates from 3D culture were subjected to Western blot analysis to validate the RPPA data.
The cell lines are 76NE6-parental (P) and with stable expression of vector (V), EL, and LMW-E and the tumor-derived cells (TDCs). (D) Linear regression
analysis of the RPPA data and the densitometry values of all the proteins analyzed by Western blot analysis in Figure 5C. The same antibodies were
used for the two types of analysis.
doi:10.1371/journal.pgen.1002538.g005
Table 3. Patient protein expression based on low and high LMW-E and EL levels by RPPA analysis.
Relative protein levels
Proteins Low LMW-E High LMW-E P value*
ERK2 2.27E-07
Median 0.47 0.542
Mean (range) 0.459 (0.134–1.02) 0.581 (0.134–1.88)
pMEK1/2 (S217) 4.85E-06
Median 0.2 0.223
Mean (range) 0.203 (0.111–0.348) 0.235 (0.112–0.806)
b-Raf 2.05E-04
Median 0.159 0.209
Mean (range) 0.198 (0.0549–0.756) 0.264 (0.069–1.505)
mTOR 5.45E-04
Median 0.099 0.127
Mean (range) 0.112 (0.043–0.297) 0.135 (0.0424–0.423)
eIF4E 7.06E-02
Median 0.356 0.392
Mean (range) 0.381 (0.143–0.777) 0.405 (0.093–0.795)
pAkt (T308) 4.67E-02
Median 0.145 0.123
Mean (range) 0.164 (0.071–0.841) 0.168 (0.068–1.362)
Low EL High EL
ERK2 0.2
Median 0.516 0.53
Mean (range) 0.521 (0.134–1.344) 0.568 (0.284–1.88)
pMEK1/2 (S217) 0.5
Median 0.212 0.216
Mean (range) 0.222 (0.111–0.806) 0.22 (0.143–0.352)
b-Raf 2.09E-05
Median 0.163 0.246
Mean (range) 0.223 (0.055–1.505) 0.292 (0.089–0.752)
mTOR 1.29E-02
Median 0.111 0.13
Mean (range) 0.121 (0.042–0.423) 0.142 (0.047–0.297)
eIF4E 5.65E-03
Median 0.362 0.416
Mean (range) 0.384 (0.093–0.795) 0.44 (0.143–0.703)
pAkt (T308) 0.9
Median 0.131 0.134
Mean (range) 0.162 (0.071–1.227) 0.184 (0.068–1.362)
*Wilcoxon ranksum test.
doi:10.1371/journal.pgen.1002538.t003
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PLoS Genetics | www.plosgenetics.org 11 March 2012 | Volume 8 | Issue 3 | e1002538Figure 6. Combination drug treatment prevents induction of aberrant acinar development by LMW-E. (A) Cells were seeded on Matrigel
for 24 hours and then treated with rapamycin, sorafenib, and roscovitine as indicated. Medium containing drugs was replaced every 4 days, and
lysates were collected on day 15 for Western blot analysis with the indicated antibodies. (B) On day 15 of Matrigel culture, cells grown as in (A) were
fixed and stained with E-cadherin (red) and Ki67 (green), and nuclei were counterstained with DAPI (blue). Scale bar=50 mm. (C) The diameters of the
acini were measured and averaged from three independent experiments. Error bars=SEM (Student t test, *p,0.05). (D) The number of Ki67-positive
cells per acinus was counted and averaged from three independent experiments. Error bars=SEM (Student t test, *p,0.05). Kaplan-Meier survival
plots demonstrating association between full length and high LMW-E on disease-specific survival. Association of:
doi:10.1371/journal.pgen.1002538.g006
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utilized three model systems (xenograft transplantation, 3D acinar
morphogenesis, and an inducible transgenic mouse model) that
recapitulate the human mammary gland to examine the tumor-
initiating potential of LMW-E.
We first demonstrated that LMW-E has greater oncogenic
potential than EL, as indicated by tumor-initiating activity in nude
mice with subcutaneous xenografts. Moreover, LMW-E expres-
sion is selected with increasing in vivo passaging suggesting that
LMW-E provides a growth advantage in tumors. Indeed, selective
pressure exerted from the in vivo microenvironment has previously
been shown to favor further genetic and epigenetic alterations that
eventually progress to highly advanced tumor stages [39].
Additionally, the inducible transgenic mouse model system
provided evidence for a direct role of LMW-E in mediating
alteration in the TEBs in the mammary gland, which is required
for tumor generation in these mice. Furthermore, this model
system underscores the important role of the microenvironment in
the development of morphological characteristics and growth
patterns.
We observed an interesting phenomenon in which tumor cells
with LMW-E expression and transgenic mice with inducible
LMW-E expression demonstrated an elevation in the level of EL
expression. We speculate that high LMW-E protein levels may
lead to hyperactive G1-S transition causing a positive feedback
loop acquired during tumor progression that activates the
transcription of the endogenous cyclin E mRNA through
activation of E2F. Increased E2F activity has been shown to
stabilize cyclin E by reducing conjugation with ubiquitin [40].
Additionally, cyclin E transcription has been reported to be
positively regulated by the E2F transcription factor, and in fact,
the cyclin E promoter does contain several E2F binding sites [41].
Indeed, this observation warrants further investigation into the
transcriptional regulation of cyclin E expression and the possible
positive feedback loop that is critical for mammary tumorigenesis.
The acinar morphogenesis assay has been widely used to model
the early stages of mammary oncogenesis [19,21]. Our data
suggest that LMW-E may exert its tumorigenic potential via
disruption of the acinar morphogenetic process resulting in larger
and misshapen acini due to failure of proliferation arrest and
apoptotic induction [30]. High Ki67 expression in the cells on the
outer layer of the acini suggests continued proliferation that likely
leads to disruption of the spherical integrity of the structures.
These aberrant morphological phenotypes mediated by LMW-E
are similar to the characteristics described for ductal carcinoma in
situ and may explain the role of LMW-E in mammary oncogenesis.
The fact that LMW-E requires CDK2 kinase activity to drive
multiacinar complexes and promote tumor-initiating activity of
hMECs in mice suggests that LMW-E itself has no intrinsic
oncogenic activity. This observation corroborates with our recent
publication demonstrating that CDK2 is necessary for LMW-E-
mediated mammary tumor formation in transgenic mice [28].
Therefore, treatment of tumors with high LMW-E protein levels
can be achieved by inhibiting CDK2 kinase activity. Roscovitine is
a promising agent for targeting multiple types of tumors, including
breast cancer, sarcoma, non-small cell lung cancer, multiple
myeloma, and lymphoma [42–46]. In fact, treatment of the mice
with LMW-E-induced tumor using two different CDK inhibitors,
meriolin and roscovitine, significantly delayed mammary tumor
formation by approximately 6 weeks [28]. In this study, we also
demonstrated that combination treatment using roscovitine
together with rapamycin or sorafenib of LMW-E-expressing acini
efficiently prevents the aberrant morphogenetic phenotypes
without toxic effects on hMECs lacking LMW-E expression.
These observations implicate an effective therapeutic strategy of
inhibiting the CDK2-associated kinase activity and perhaps
combining it with rapapmycin or sorafenib to treat breast cancer
patients with high LMW-E expression.
The results from the proteomic analysis demonstrated a marked
contrast in the protein expression profiles of cells grown on
monolayer and cells grown in 3D culture and illustrated a high
similarity between cells in 3D culture and human tumor tissues,
thus establishing a bridge between the 3D culture system and
human tissues and further supporting the use of this culture system
for biological study [47]. In fact, gene expression signatures of
mammary cells extracted from this 3D culture system can be
reliably used to predict patient outcome in which the signature of
growth-arrested and well-organized hMECs predicts favorable
clinical outcome [48,49]. Data from this study also allowed for the
delineation of a signaling pathway that is deregulated in breast
cancer patients who express high LMW-E levels. We demonstrat-
ed that tumors and cell lines with high LMW-E expression have
upregulated b-Raf-ERK1/2-mTOR signaling, which has been
reported to result in enhanced cell survival and reduced apoptosis
[50–52]. Future pre-clinical studies will be aimed at examining if
human breast tumors with high LMW-E expression are selectively
sensitive to combination therapy with roscovitine, and sorafenib or
rapamycin as compared with those without high LMW-E. These
studies will help establish the clinical relevance of LMW-E
expression as a marker for the targeted therapies identified in
this report.
In summary, LMW-E/CDK2 deregulates mammary acinar
development, leading to enlarged and misshapen structures.
Failure of LMW-E-expressing acini to arrest proliferation and
undergo luminal apoptosis suggests upregulation of signaling
involving cell survival and growth by hyperactive LMW-E/CDK2
complexes. Our data suggest that the combination of roscovitine
with either rapamycin or sorafenib should be evaluated as a
therapeutic strategy to treat breast cancer patients with high
LMW-E expression.
Methods
Constructs and cell culture
All immortalized cell lines were cultured in DFCI-1 medium as
described previously [53]. FLAG-tagged cyclin E gene constructs
EL and LMW-E(T1) were cloned into the pcDNA 4.0 vector
(Clontech, Mountain View, CA) and transfected into 76NE6
hMECs. Transfected cells were selected with 80 mg/mL zeocin
(Invitrogen), and stable transfectants were maintained in culture
with 10 mg/mL zeocin.
Figure 7. Activated b-Raf-ERK1/2-mTOR signaling pathway and high LMW-E expression predict poor survival in breast cancer
patients. Kaplan-Meier survival plots demonstrating association between full length (EL) and high LMW-E on disease specific survival. Association of
(A) LMW-E and full length level, (B) Combination of FAK, BIM, Akt and pAkt (T308) protein levels in patients with high full length or high LMW-E, (C)
FAK, BIM, Akt and pAkt (T308) protein levels in patients with high LMW-E. The expression levels of FAK, BIM, Akt and pAkt (T308) were dichotomized
using their median values from all 276 patient samples. E (events)/N (total number), refer to number of patients who die of breast cancer/total
number of patients in the group being analyzed. All p values are based on log-rank test. The overall p value of comparison amongst the 4 different
groups is p,0.0001.
doi:10.1371/journal.pgen.1002538.g007
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expression we used a similar strategy to the one we used for
generation of the inducible cyclin E expression in MCF-7 cells
[27]. Specifically, the cyclin E gene constructs were cloned into the
pRetro-CMV/TO vector and transfected into 293T cells to
produce retroviruses carrying the cyclin E constructs, and the
pBMN-BSR-TetR vector to produce retroviruses carrying the Tet
repressor.The 76NE6 cells were infected first with the retroviruses
carrying the Tet repressor (TetR) gene fused with blasticidin-S
resistance gene and then with the retroviruses carrying the cyclin E
constructs. 76NE6 cells inducibly expressing TetR-vector, EL,
LMW-E(T1), EL
R130A, and LMW-E(T1
R130A), were maintained
in DFCI-1 medium with 20 mg/ml blasticidin-S and 1 mg/ml
puromycin (InvivoGen, San Diego, CA). Other cell lines used in
this study (i.e. Hs578T and MDA-MB-231) were obtained from
American Type Tissue Collection and cultured as described
previously [54].
Tumorigenic assay and in vivo passaging
Nude mice were purchased from Charles River Laboratories
(Wilmington, MA) and maintained in the Department of
Veterinary Medicine at The University of Texas MD Anderson
Cancer Center. The mice were injected subcutaneously in the
mammary fat pad with 1610
6 cells suspended in 100 mL of a 1:1
Matrigel:media mix (Matrigel from BD Biosciences, San Diego,
CA). Doxycycline was added to drinking water containing 1%
sucrose, and water was replaced twice weekly. Mice were
sacrificed under an Animal Care and Use Committee (ACUF)-
approved protocol when tumors reached approximately 12 mm in
diameter or 10 weeks after injection, whichever came first. The
tumors were harvested for histopathological analysis or for
expansion of tumor cells in tissue culture for reinjection into mice
for in vivo passaging. Tumors submitted for histopathology were
fixed in 10% neutral buffered formalin, paraffin embedded, and
serially sectioned at 5 mm thickness.
Reverse transcriptase PCR and real-time (RT–PCR)
RNA was isolated from mammary glands and tumors by using
the RNAeasy kit (Qiagen). Reverse transcription (RT) was
performed using the First Strand cDNA Synthesis Kit using
1 mg of mRNA per reaction (Roche). Real-time PCR was
performed on the reverse-transcribed samples using SYBR Green
PCR Master Mix (Applied Biosystems). RT reactions in which no
reverse transcriptase had been added served as a monitor for the
efficiency of the DNase I digestion. All reactions were carried out
in triplicate. The fold difference in mouse cyclin E transcripts was
calculated by the DDCT method using GAPDH as the internal
control. For every reaction, we observed a single peak on the
dissociation curve plot. Primer sequences were as follows: cyclin E-
F, 59-CAGAGCAGCGAGCAGGAGA-39; cyclin E-R, 59 CAG-
CTGCTTCCACACCACTG-39; GAPDH-F, 59-TGTACCGTC-
TAGCATATCTCCGAC-39; GAPDH-R, 59-ATGATGTGCT-
CTAGCTCTGGGTG-39.
Transgenic mice
Transgenic mice with conditional expression of LMW-E were
generated using the tetracycline regulatory system by cloning the
coding sequence of LMW-E downstream of the minimal Tet
operator in TMILA plasmid (a gift from L. A. Chodosh,
University of Pennsylvania, Philadelphia, PA). Additionally, an
IRES-firefly luciferase expression cassette was cloned downstream
of LMW-E to serve as a surrogate reporter for transgene
expression. Two founder mice (line 4372 and line 4382) harboring
this TetO-LMW-E transgene (referred to as TLMW) were mated to
a transgenic mouse harboring the MMTV-rtTA-pA transgene
(referred to as MTB) to yield bi-transgenic MTB/TLMW mice
[55]. Bi-transgenic mice carrying both of these transgenes express
the rtTA transactivator in the mammary epithelium but do not
express LMW-E unless doxycycline is added. TLMW founder line
was generated by pronuclear injection and crossed with MTB
mice. Whole-mount and bromodeoxyuridine (BrdU) staining were
done as previously described [32].
Staining of tumor sections
Paraffin-embedded tumor sections were stained with hematox-
ylin and eosin and for cyclin E using a polyclonal anti-cyclin E
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The
immunostaining was done as previously described [32] using a
Vectastain ABC kit (per manufacturer’s web site) and a BCIP/
NBT chromogen detection system (Vector Laboratories, Burlin-
game, CA). Briefly, the sections were incubated in 1% H2O2 to
block endogenous peroxidase activity and then incubated for
20 min in 10 mmol/L sodium citrate buffer (pH 6.0) at 90uCt o
retrieve nuclear antigens. Both primary and secondary antibody
incubations were performed for 1 hr in blocking buffer (5% bovine
serum albumin and 0.5% Tween-20 in 16 phosphate-buffered
saline [PBS]) at room temperature. Nuclei were counterstained
with hematoxylin.
Transwell invasion assay
For each sample, 100 ml of 1 mg/ml Matrigel in serum free-
cold MEM media was aliquoted into the upper chamber of 24-well
transwell plate (Corning, Corning, NY) and incubated at 37uC for
at least 4–5 hours for adequate gelling. The cells were washed and
suspended in serum free medium at a 1610
6 cells/ml concentra-
tion. One hundred ml of cell suspension was transferred onto the
upper chamber containing the Matrigel layer. The lower chamber
of the transwell was filled with 600 ml of complete media
containing 10 mg/ml fibronectin as an adhesive substrate. After
24 hours, the cells were fixed with 4% formaldehyde for
15 minutes, rinsed with PBS, and stained with 0.2% crystal violet
for 10 minutes. The crystal violet was rinsed with excess ddH2O
and the top chamber containing the Matrigel was thoroughly
cleansed with Q-tips and the invaded cells were photographed
with a light microscope. For quantification, the cells on the top
and bottom of the chamber are collected using trypsin and
counted using the culture counter. Each sample was counted 3
times and each experiment was repeated independently 3 times.
Morphogenesis assay and drug treatment
3D culture on basement membrane was performed as described
previously [21]. Assay medium (DFCI-1 medium with 2% growth
factor-reduced Matrigel) with or without drugs was replaced every
4 days, and cells were cultured for 15 days.
Indirect immunofluorescence analysis
Indirect immunofluorescence analysis of 3D cultures was
performed as previously described with minor modifications
[56]. Cells cultured in 8-well chamber slides were fixed with 2%
paraformaldehyde at room temperature for 20 min, permeabilized
with 1% Triton X-100 in PBS for 20 min, washed thrice with
PBS/glycine buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM
NaH2PO4, and 100 mM glycine), and blocked with IF buffer
(130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM
NaN3, 0.1% bovine serum albumin, 0.2% Triton X-100, and
0.05% Tween-20) plus 10% goat serum for 1 hr at room
temperature. Primary antibodies (laminin V and a6-integrin
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cadherin [BD Biosciences], and Ki67 [Abcam, Cambridge,
MA]) were incubated in IF buffer at 1:200 dilution overnight at
4uC. The cells were incubated with Alexa fluor-conjugated rabbit
(488), mouse (594), or rat (680) secondary antibodies (Molecular
Probes, Carlsbad, CA), counterstained with 4,6-diamidino-2-
phenylindole (DAPI) (Sigma, St. Louis, MO) for 15 min at room
temperature, and mounted with antifade solution (Molecular
Probes). Confocal microscopy was performed at room temperature
using an Olympus FV300 laser scanning confocal microscope
(Olympus America, Inc., Center Valley, PA) at 406magnification,
and images were processed using Adobe Photoshop (Version
11.0.2). For quantification, the diameter of each acinus was
measured, and unpaired Student t test was used for statistical
analysis.
Protein isolation for Western blot and kinase assay
Cell lysates were prepared and subjected to Western blot
analysis as described previously [12]. To obtain lysates from acini,
acini were washed once with cold PBS, scraped, collected, and
washed twice with cold PBS. Cell recovery solution (BD
Biosciences) was added to the Matrigel/acini mixture at 1:1
volume, and cells were incubated on ice for 1 hr, washed with
PBS, and lysed as described previously [13] The protein blots were
incubated with primary antibodies (cyclin E, vinculin [Santa
Cruz], b-actin [Chemicon], BIM [StressGen Biotechnologies,
Victoria, British Columbia], FAK, b-Raf, ERK1/2, pERK1/2
(T202/Y204), pMEK1/2 (S217/221), pS6 (S235/236), mTOR,
eIF4E, Akt, pAkt(T308), and pRb(S807/811) [Cell Signaling
Technology, Danvers, MA]) at 4uC with gentle shaking overnight.
Kinase assay with histone H1 and GST-Rb as cyclin E
substrates was performed as described previously [13].
Reverse-phase protein array (RPPA) analysis
The RPPA approach was performed as previously described
[34]. Cellular proteins that were prepared as described for western
blotting were denatured by boiling in 1% SDS (with beta-
mercaptoethanol) and diluted in five 2-fold serial dilutions in
dilution buffer (lysis buffer containing 1% SDS). Serial diluted
lysates were arrayed on nitrocellulose-coated slides (Grace Biolab)
using Aushon 2470 Arrayer (Aushon BioSystems). Each sample
was robotically printed in 5 fold serial dilutions on multiple slides
including positive and negative controls prepared from mixed cell
lysates or dilution buffer, respectively, as well as multiple cell lines
incubated with and without growth factors to provide dynamic
range.
Each slide was probed with a validated primary antibody plus a
biotin-conjugated secondary antibody. Antibody targets were
selected as being relevant to breast cancer through a literature
review. Antibodies where then obtained and validated against each
potential target. Only antibodies with a Pearson correlation
coefficient between RPPA and western blotting of greater than 0.7
were used in reverse phase protein array study. Antibodies with a
single or dominant band on western blotting were further assessed
by direct comparison to RPPA using cell lines with differential
protein expression or modulated with ligands/inhibitors or siRNA
for phospho- or structural proteins, respectively.
The signal obtained was amplified using a Dako Cytomation-
catalyzed system (Dako) and visualized by DAB colorimetric
reaction. The slides were scanned, analyzed, and quantified using
a customerized-software Microvigene (VigeneTech Inc.) to
generate spot intensity.
Each dilution curve was fitted with a logistic model (‘‘Super-
curve Fitting’’ developed by the Department of Bioinformatics and
Computational Biology in MD Anderson Cancer Center, ‘‘http://
bioinformatics.mdanderson.org/OOMPA’’). This fits a single
curve using all the samples (i.e., dilution series) on a slide with
the signal intensity as the response variable and the dilution steps
are independent variable. The fitted curve is plotted with the
signal intensities – both observed and fitted - on the y-axis and the
log2-concentration of proteins on the x-axis for diagnostic
purposes. The protein concentrations of each set of slides were
then normalized by median polish, which was corrected across
samples by the linear expression values using the median
expression levels of all antibody experiments to calculate a loading
correction factor for each sample.
Breast cancer patient samples and clinical data
The clinical data from 267 breast cancer patients used in this
study were reported previously [16]. Each patient had received a
diagnosis of breast cancer between 1990 and 1995 at 1 of 12
hospitals in the Chicago area. The study was approved by the
institutional review board of the Wadsworth Center (Albany, NY).
In the study reported herein, we used tissue samples from a portion
of these for RPPA analysis to investigate large-scale protein
expression pattern.
Statistical analysis
Each cell culture experiment was performed at least three times.
Continuous outcomes were summarized with means and standard
deviations. Comparisons among groups were analyzed by two-
sided t test and Wilcoxon rank-sum test. These analyses were
performed using SPSS software, version 12.0. The differences in
tumor incidence between groups (for Table 1 and Table 2) were
compared using Fisher’s exact test. The analyses were performed
using SAS (version 9.2).
For analysis of the RPPA data, the SuperCurve quantified
concentration of the proteins were natural log transformed. The
differences in protein expression levels between high- and low
LMW-E or EL expressed patient groups were assessed using
Wilcoxon Rank Sum test. For the hierarchical clustering of the 71
proteins common between the 2D culture, 3D culture and patient
data sets, the data for each protein in each data set were
standardized (subtraction of mean then divided by standard
deviation) separately, and then the standardized data were
combined. The combined data set contains 93 cell line samples
from 2D and 3D each, with three technical replicates for each of
the 31 unique samples, and 276 breast tumor patient samples.
Disease-specific survival (DSS) was calculated from the date of
surgical resection of the primary tumor to the date of death or last
follow-up. Data for patients who died from causes other than
breast cancer were censored at the time of death. DSS curves were
computed by the Kaplan-Meier method [57]. Bivariate analyses of
DSS in patients with high LMW-E expression according to levels
of FAK, BIM, total Akt, and pAkt(T308) were performed with the
use of a two-sided log-rank test [58]. Kaplan-Meier survival curves
were calculated for the different cyclin E groups, and the log-rank
test was used to compare the disease-free survival among groups.
Stata statistical software (SE 9, StataCorp LP, College Station,
TX) was used for these statistical analyses. All P values were 2
tailed, and p,0.05 was considered significant.
Supporting Information
Figure S1 LMW-E overexpression causes elevation of cyclin E
protein and mRNA levels. (A) Cells were grown on Matrigel for 15
days and RNA were extracted and subjected to qRT-PCR analysis
for the mRNA level of cyclin E and normalized against GAPDH
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test. (B) Mouse GAPDH and mouse cyclin E mRNA expression
levels in tumor and contralateral mammary gland of 3 different
LMW-E overexpressing transgenic mice. Quantitative real-time
PCR (qRT–PCR) was performed on a 7300 Real-Time PCR
System from Applied Biosystems.
(PPT)
Figure S2 Hierarchichal clustering of patient samples and
proteins using the top 50 differentially expressed proteins between
high and low LMW-E or EL. Proteins were ranked by the p-values
based on two-sample t-test on the natural log transformed
concentration. Row side color indicates cyclin E expression.
(Red: samples with low cyclin E expression; blue: samples with
high cyclin E expression.) (A) Use the top 50 differentially
expressed proteins between high and low EL. (B) Use the top 50
differentially expressed proteins between high and low LMW-E.
(PPT)
Figure S3 Box plots of protein expression in patient tumors by
low versus high cyclin E levels. Differences in the expression of
these proteins between samples with high and low LMW-E or
between high and low EL cyclin E were compared using the
Wilcoxon Rank-Sum tests.
(PPT)
Figure S4 Combination drug treatment prevents induction of
aberrant acinar development by LMW-E. Cells were seeded on
Matrigel for 24 hours and then treated as indicated. Medium
containing drugs was replaced every 4 days. On day 15 of Matrigel
culture, cells were fixed and stained with E-cadherin (red) and
Ki67 (green), and nuclei were counterstained with DAPI (blue).
Scale bar=50 mm. (B) The diameters of the acini were measured
and averaged from three independent experiments. Error
bars=SEM (Student t test, *p,0.05). (C) The number of Ki67-
positive cells per acinus was counted and averaged from three
independent experiments. Error bars=SEM (Student t test,
*p,0.05).
(PPT)
Figure S5 Combination drug treatment prevents induction of
aberrant acinar development by LMW-E. (Quantitation of the
study from Figure S4) Cells were seeded on Matrigel for 24 hours
and then treated as indicated. Medium containing drugs was
replaced every 4 days. (A) On day 15 of Matrigel culture, the
diameters of the acini were measured and averaged from three
independent experiments. Error bars=SEM (Student t test,
*p,0.05). (B) The number of Ki67-positive cells per acinus was
counted and averaged from three independent experiments. Error
bars=SEM (Student t test, *p,0.05).
(PPT)
Figure S6 Activated b-Raf-ERK1/2-mTOR signaling pathway
and high EL expression does not predict poor survival in breast
cancer patients. Kaplan-Meier survival plots demonstrating
association between full length and high LMW-E in association
with FAK, BIM, Akt and pAkt (T308) protein levels obtained from
RPPA analysis.
(PPT)
Figure S7 High EL expression does not associate with the b-
Raf-ERK1/2-mTOR pathway to predict patient DSS. Kaplan-
Meier survival plots demonstrating association between combina-
tion of FAK, BIM, Akt and pAkt (T308) protein levels on disease-
specific survival in patients with high full length. The expression
levels of FAK, BIM, Akt and pAkt (T308) were dichotomized
using their median values from all 276 patient samples. All p
values are based on log-rank test.
(PPT)
Table S1 List of proteins used in the RPPA assay.
(DOC)
Table S2 Proteins that show distinct expression pattern between
2D and 3D cultures.
(DOC)
Table S3 Disease-specific survival rates of proteins that associate
with high LMW-E protein levels.
(PPT)
Table S4 Statistical analysis of the effects of the combination
drug treatment on acinar diameter.
(PPT)
Table S5 Statistical analysis of the effects of the combination
drug treatment on the percentage of Ki67-positive acini.
(PPT)
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